Author

R. J. Dikdan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. K. Choudhary· 1 shared A. Kolloli· 1 shared A. Mattappallil· 1 shared A. Pinter· 1 shared A. Rosania· 1 shared A. Shelke· 1 shared C. Grady· 1 shared C. Levine· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. K. Choudhary

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Broad-Spectrum Heavily Mutated Monoclonal Antibody Isolated from COVID-19 Convalescent Vaccinee with Capacity to Neutralize SARS-CoV2 Variants Ranging from B.1 to BQ.1.1

A. K. Choudhary, D. Calianese, W. Honnen, A. Kolloli, R. J. Dikdan, D. Jaijyan, G. Song, T. Capozzola, V. Akkaraju, A. Mattappallil, A. Rosania, S. Khan, M. Lerman, N. Afzal, S. Subbian, , A. Pinter

The paper isolates and characterizes Acovimab, a broadly neutralizing monoclonal antibody against SARS-CoV-2 variants, showing potent neutralization against most variants except XBB.1.5 and synergistic activity with Sotrovimab.

bioRxiv · May 4, 2023 · PreprintImmunology

Development of amidase-dependent pyrazinoic acid prodrugs with activity against pyrazinamide resistant Mycobacterium tuberculosis

C. Levine, R. Jadhav, P. Yan, K. Tsotetsi, X. Wang, D. Awasthi, C. Grady, A. Shelke, S. S. Daher, T. Richmann, R. Shrestha, P. Sukheja, J. Patel, P. R. Barnett, R. J. Dikdan, , P. Kumar

This paper develops amidase-dependent pyrazinoic acid prodrugs that bypass PncA activation, showing efficacy against PZA-resistant Mtb.

bioRxiv · Jul 5, 2022 · PreprintMicrobiology